VC Deals Analysis: Hemodialysis Stands Out In Feb 5-Year Famine
February’s total deal value hit a five-year low in the absence of large venture fundraisings. However, amongst the companies that succeeded in raising cash, those in the area of hemodialysis management attracted more investor interest than usual.
You may also be interested in...
VC Deals Analysis: From Famine To Feast, 2017 Bloats With May Haul
The venture financing climate has been somewhat dull so far this year but the investment activity levels enjoyed a much-needed boost in May. The month's haul of transactions not only brought in the quantity – with the highest deal volume to date – but also quality, high-value rounds.
Big Pharma Helps Pour $900m Into Grail
The biggest venture funding round in history, pan-cancer screening test developer Grail has reeled in $900m in the first close of what it hopes will be a $1bn Series B round.
Since its inception in 2010, the Singapore-Stanford Biodesign innovation training program has led to the filing of more than 22 patents and seven publicly funded projects. Of these seven projects, two have progressed to become start-ups – Advent Access and Privi Medical.